The company has worldwide rights to VitroGro® which has particular commercial applications in wound healing and tissue regeneration.
The clinical trial will be conducted by Professor Keith Harding and is expected to be completed by 2010 year end.
This clinical trial will be used to produce the final data necessary for approval of VitroGro® for sale, initially in Europe, Canada, Australia and New Zealand.
Dr Steven Mercer, chief executive officer of Tissue Therapies said today, “Professor Harding is widely recognised as one of the most eminent wound healing physicians and researchers in the world today."
"His expertise and that of his whole team will be invaluable to Tissue Therapies for this human trial.”
The human trial forms a part of the company's commercialisation plan for the sale of VitroGro® wound healing products.
Disclosure: I do not hold a position